Jan. 12 at 2:30 PM
$CDXS $MRVI Interesting!
Michael Kamdar, CEO of the enzymatic DNA synthesis company Molecular Assemblies, which received a
$10 million investment from the enzyme engineering firm Codexis in November, says Leproust’s evaluation of enzymatic synthesis is unnecessarily gloomy. He maintains that enzymatic synthesis is better at building long strands of DNA, even though the technology is still young."
https://www.businesswire.com/news/home/20250128647933/en/Maravai-LifeSciences-Acquires-Assets-and-Intellectual-Property-from-Molecular-Assemblies
